Trial
NCT03567291
Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborators
Nuvelution TS Pharma, Inc.
Condition
Tourette Syndrome
Intervention
TEV-50717
Why stopped
The parent trials did not meet the primary endpoints of reduction in motor and phonic tics.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-09